Unichem Laboratories schedules 63rd AGM for August 11

0 min read     Updated on 11 Jun 2026, 02:57 AM
scanx
Reviewed by
Jubin VScanX News Team
AI Summary

Unichem Laboratories Limited has announced its 63rd Annual General Meeting for August 11, 2026, via video conference. The cut-off date for determining shareholder eligibility to vote is August 4, 2026.

powered bylight_fuzz_icon
42630658

*this image is generated using AI for illustrative purposes only.

Unichem Laboratories Limited has scheduled its 63rd Annual General Meeting for August 11, 2026, to be conducted via video conference or other audio-visual means. The meeting allows shareholders to vote on key resolutions, with eligibility determined by a specified cut-off date.

The cut-off date for ascertaining shareholders eligible to vote at the 63rd AGM is August 4, 2026. Members whose names appear in the register of members on this date will be entitled to participate and vote.

The intimation was addressed to BSE Ltd. and the National Stock Exchange of India Ltd. The communication was signed by Pradeep Bhandari, Head – Legal & Company Secretary, on behalf of unichem laboratories .

Meeting Details

Event Date
63rd Annual General Meeting August 11, 2026
Cut-off Date for Voting Eligibility August 4, 2026

Historical Stock Returns for Unichem Laboratories

1 Day5 Days1 Month6 Months1 Year5 Years
-1.71%+21.18%+20.78%-3.48%-30.22%+32.48%

What are the key resolutions proposed for the 63rd AGM, and how might they impact Unichem's strategic direction?

How will the virtual format of the AGM influence shareholder participation and voting outcomes?

What are the expected financial highlights or performance updates to be shared during the meeting?

Unichem FY26 Net Profit Rises 84% to ₹252.84 Crore

2 min read     Updated on 25 May 2026, 06:21 PM
scanx
Reviewed by
Anirudha BScanX News Team
AI Summary

Unichem Laboratories reported a full-year net profit of ₹252.84 crore for FY26, up 84% from the previous year, despite a decline in Q4 profit to ₹10.91 crore. Annual revenue grew to ₹2,201.85 crore. The board approved the re-appointment of the Managing Director & CEO and auditors.

powered bylight_fuzz_icon
41003531

*this image is generated using AI for illustrative purposes only.

Unichem Laboratories has announced its financial results for the quarter and year ended March 31, 2026. The company reported a consolidated net profit of ₹10.91 crore for the fourth quarter, compared to ₹52.97 crore in the corresponding period of the previous year. Revenue from operations for the quarter stood at ₹575.12 crore, while total income was ₹598.59 crore. EBITDA for the quarter declined to ₹34.90 crore from ₹83.70 crore in the same period last year, with the EBITDA margin contracting to 6.07% from 14.25% year-on-year.

For the full year ended March 31, 2026, the company posted a net profit of ₹252.84 crore, an increase from ₹137.52 crore in the previous year. Revenue from operations for the fiscal year rose to ₹2,201.85 crore from ₹2,110.97 crore in the prior year. The board has approved the audited financial statements for the year.

Consolidated Financial Performance

The company's financial performance for the quarter and year reflects the impact of exceptional items and operational adjustments. Key metrics from the consolidated results are presented below:

Particulars: Q4 FY26 (₹ Crores) Q4 FY25 (₹ Crores) FY26 (₹ Crores) FY25 (₹ Crores)
Revenue from Operations 575.12 587.18 2,201.85 2,110.97
Total Income 598.59 596.43 2,264.91 2,146.29
Total Expenses 567.44 538.63 2,174.39 1,991.70
Net Profit for the Period 10.91 52.97 252.84 137.52
Basic EPS (₹) 1.55 7.52 35.91 19.53

The quarterly EBITDA performance highlights a significant year-on-year compression in operating profitability, as summarised below:

Metric: Q4 FY26 Q4 FY25 Change (YoY)
EBITDA (₹ Crores) 34.90 83.70 Decline
EBITDA Margin (%) 6.07% 14.25% Contraction

Exceptional items for the year included an employee benefit expense of ₹15.40 crore due to the implementation of new labour codes and interest on a European commission fine of ₹58.26 crore. Additionally, the company recognized a net gain of ₹1.99 crore from the sale of its subsidiary, Unichem Laboratories Ireland, which ceased to be a subsidiary effective April 30, 2025.

Board Decisions and Appointments

The Board of Directors, in its meeting held on May 22, 2026, approved several key resolutions. Mr. Pabitrakumar Bhattacharyya was redesignated from 'Managing Director' to 'Managing Director & Chief Executive Officer' effective immediately. Furthermore, the board approved his re-appointment as Managing Director and Chief Executive Officer for a further period of three years from August 10, 2026, to August 9, 2029, subject to shareholder approval.

The board also re-appointed M/s. Kishore Bhatia & Associates as Cost Auditors and M/s. Ram Agarwal & Associates as Internal Auditors for the financial year 2026-27. The statutory auditors, M/s. N. A. Shah Associates LLP, have issued an unmodified opinion on the annual audited financial results for both standalone and consolidated entities.

Historical Stock Returns for Unichem Laboratories

1 Day5 Days1 Month6 Months1 Year5 Years
-1.71%+21.18%+20.78%-3.48%-30.22%+32.48%

How will Unichem Laboratories' management plan to recover the EBITDA margin from 6.07% back toward historical levels in FY27, and which business segments are expected to drive this recovery?

What is the potential financial impact of the European Commission fine on Unichem's future cash flows, and are there any ongoing legal proceedings that could result in additional penalties?

Following the divestiture of Unichem Laboratories Ireland, is the company considering further portfolio restructuring or additional subsidiary exits to streamline operations and improve profitability?

More News on Unichem Laboratories

1 Year Returns:-30.22%